JPWO2020247371A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020247371A5 JPWO2020247371A5 JP2021571942A JP2021571942A JPWO2020247371A5 JP WO2020247371 A5 JPWO2020247371 A5 JP WO2020247371A5 JP 2021571942 A JP2021571942 A JP 2021571942A JP 2021571942 A JP2021571942 A JP 2021571942A JP WO2020247371 A5 JPWO2020247371 A5 JP WO2020247371A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- macrophages
- bone marrow
- syndrome
- marrow cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962857169P | 2019-06-04 | 2019-06-04 | |
| US62/857,169 | 2019-06-04 | ||
| US201962867569P | 2019-06-27 | 2019-06-27 | |
| US62/867,569 | 2019-06-27 | ||
| US201962947948P | 2019-12-13 | 2019-12-13 | |
| US62/947,948 | 2019-12-13 | ||
| US202063032214P | 2020-05-29 | 2020-05-29 | |
| US63/032,214 | 2020-05-29 | ||
| PCT/US2020/035702 WO2020247371A1 (en) | 2019-06-04 | 2020-06-02 | Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022535550A JP2022535550A (ja) | 2022-08-09 |
| JPWO2020247371A5 true JPWO2020247371A5 (pt) | 2023-06-12 |
Family
ID=73651973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571942A Pending JP2022535550A (ja) | 2019-06-04 | 2020-06-02 | 骨髄細胞炎症性表現型を調節するための抗ｐｓｇｌ－１組成物及び方法、ならびにその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220396632A1 (pt) |
| EP (1) | EP3980463A4 (pt) |
| JP (1) | JP2022535550A (pt) |
| KR (1) | KR20220042055A (pt) |
| CN (1) | CN114401990A (pt) |
| AU (1) | AU2020288823A1 (pt) |
| BR (1) | BR112021024242A2 (pt) |
| CA (1) | CA3141334A1 (pt) |
| IL (1) | IL288510A (pt) |
| TW (1) | TW202110891A (pt) |
| WO (1) | WO2020247371A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2584664B (en) * | 2019-06-10 | 2023-05-24 | Newcells Biotech Ltd | Improved retinal organoids and methods of making the same |
| CN116380755B (zh) * | 2023-03-20 | 2023-11-21 | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | CD127+PMN-MDSCs在诊断支气管肺发育不良中的应用及诊断试剂盒 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1274839A2 (en) * | 2000-03-24 | 2003-01-15 | Genetics Institute, LLC | A p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor |
| US7744888B2 (en) * | 2001-08-03 | 2010-06-29 | Abgenomics Cooperatief U.A. | Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies |
| MY148646A (en) * | 2004-05-10 | 2013-05-15 | Abgenomics Cooperatief Ua | Anti-psgl-1 antibodies |
| US20110212096A1 (en) * | 2006-12-01 | 2011-09-01 | Scott Rollins | Anti-p-selectin antibodies and methods of their use and identification |
| EP3388527A1 (en) * | 2008-05-15 | 2018-10-17 | Tetherex Pharmaceuticals Corporation | Anti-psgl-1 antibodies and methods of identification and use |
| RU2603097C2 (ru) * | 2010-12-21 | 2016-11-20 | Селексис Фармасьютикалс Корпорейшн | Антитела к р-селектину и способы их применения и идентификации |
| US20210017281A1 (en) * | 2016-04-15 | 2021-01-21 | Immunext, Inc. | Anti-human vista antibodies and use thereof |
-
2020
- 2020-06-02 BR BR112021024242A patent/BR112021024242A2/pt unknown
- 2020-06-02 US US17/615,863 patent/US20220396632A1/en active Pending
- 2020-06-02 AU AU2020288823A patent/AU2020288823A1/en not_active Abandoned
- 2020-06-02 JP JP2021571942A patent/JP2022535550A/ja active Pending
- 2020-06-02 TW TW109118529A patent/TW202110891A/zh unknown
- 2020-06-02 EP EP20818905.0A patent/EP3980463A4/en active Pending
- 2020-06-02 WO PCT/US2020/035702 patent/WO2020247371A1/en unknown
- 2020-06-02 CN CN202080055123.9A patent/CN114401990A/zh active Pending
- 2020-06-02 KR KR1020217040138A patent/KR20220042055A/ko unknown
- 2020-06-02 CA CA3141334A patent/CA3141334A1/en active Pending
-
2021
- 2021-11-29 IL IL288510A patent/IL288510A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240082307A1 (en) | Diagnostic methods for t cell therapy | |
| US9828435B2 (en) | Use of antibodies or antigen-binding fragments thereof that specifically bind semaphorin-4D to increase tumor infiltrating leukocyte frequency | |
| ES2961666T3 (es) | Métodos para determinar la dosificación de células CAR-T | |
| KR20180011250A (ko) | T 세포 요법을 위해 환자를 컨디셔닝하는 방법 | |
| US10983128B2 (en) | CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy | |
| JP2021521137A (ja) | 腫瘍微小環境の特性を使用するキメラ受容体ｔ細胞治療 | |
| JP2018512397A (ja) | 癌治療の有効性を高めるための組成物及び方法 | |
| US20220378830A1 (en) | Chimeric antigen receptor t cell therapy | |
| CN114901295A (zh) | 嵌合抗原受体t细胞疗法 | |
| JP2024038034A (ja) | 膀胱癌の抗ｐｄ－ｌ１抗体治療 | |
| US20220016165A1 (en) | Chimeric antigen receptor t cell therapy | |
| JPWO2020247372A5 (pt) | ||
| JPWO2020247371A5 (pt) | ||
| WO2019232479A2 (en) | Biomarkers, uses thereof for selecting immunotherapy intervention, and immunotherapy methods | |
| TW202238129A (zh) | Ｔ細胞療法 | |
| JPWO2020263651A5 (pt) | ||
| EP4007774A1 (en) | Combined inhibition of semaphorin-4d and tgfb and compositions therefor | |
| JPWO2021243169A5 (pt) | ||
| JPWO2020263650A5 (pt) | ||
| US20240158869A1 (en) | Factors for optimizing immunotherapy | |
| JP2024507199A (ja) | 免疫療法を選択するための遺伝子マーカー |